Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Wednesday

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $1.06 per share for the quarter.

Ligand Pharmaceuticals (LGND) opened at $152.54 on Wednesday. Ligand Pharmaceuticals has a 52 week low of $95.08 and a 52 week high of $170.30. The company has a market cap of $3,220.00, a PE ratio of 221.07, a P/E/G ratio of 1.61 and a beta of 1.07. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05.

A number of brokerages recently commented on LGND. BidaskClub upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 5th. Craig Hallum reiterated a “buy” rating and issued a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, November 15th. HC Wainwright set a $157.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 24th. Deutsche Bank lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price target on the stock. in a research note on Monday, November 20th. Finally, Roth Capital set a $158.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Ligand Pharmaceuticals has a consensus rating of “Buy” and an average price target of $150.83.

In other Ligand Pharmaceuticals news, CEO John L. Higgins sold 5,269 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $142.53, for a total value of $750,990.57. Following the completion of the sale, the chief executive officer now owns 143,542 shares of the company’s stock, valued at approximately $20,459,041.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John L. Higgins sold 22,500 shares of the business’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $165.00, for a total transaction of $3,712,500.00. Following the completion of the sale, the chief executive officer now directly owns 111,700 shares of the company’s stock, valued at approximately $18,430,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,852 shares of company stock worth $10,915,823. 8.30% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/ligand-pharmaceuticals-lgnd-to-release-quarterly-earnings-on-wednesday.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply